Ravi B Patel, Frank E Silvestry, Jan Komtebedde, Scott D Solomon, Gerd Hasenfuß, Sheldon E Litwin, Barry A Borlaug, Matthew J Price, Rami Kawash, Scott L Hummel, Donald E Cutlip, Martin B Leon, Dirk J van Veldhuisen, Andreas J Rieth, Scott McKenzie, Heiko Bugger, Jeremy A Mazurek, Samir R Kapadia, Marc Vanderheyden, Bonnie Ky, Sanjiv J Shah
IMPORTANCE: Although the results of A Study to Evaluate the Corvia Medical Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients with Heart Failure (REDUCE LAP-HF II) trial were neutral overall, atrial shunt therapy demonstrated potential efficacy in responders (no latent pulmonary vascular disease and no cardiac rhythm management device). Post hoc analyses were conducted to evaluate the effect of shunt vs sham stratified by responder status. OBJECTIVE: To evaluate the effect of atrial shunt vs sham control on cardiac structure/function in the overall study and stratified by responder status...
April 17, 2024: JAMA Cardiology